SHYNDEC(SH:600420) Tong Hua Shun Cai Bao·2025-04-28 08:32Financial Performance - The company reported a basic earnings per share of 0.2695 yuan for Q1 2025, representing a 9.11% increase compared to 0.2470 yuan in Q1 2024 and a significant rise from 0.1529 yuan in Q1 2023 [1] - The net profit for Q1 2025 was 3.61 billion yuan, up 9.06% from 3.31 billion yuan in Q1 2024 and a substantial increase from 1.79 billion yuan in Q1 2023 [1] - Operating revenue decreased to 26.07 billion yuan in Q1 2025, down 16.52% from 31.23 billion yuan in Q1 2024 and also lower than 34.17 billion yuan in Q1 2023 [1] - The return on equity (ROE) improved to 2.70% in Q1 2025 from 2.64% in Q1 2024 and 1.72% in Q1 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 82,576.74 million shares, accounting for 61.56% of the circulating shares, which is a decrease of 2,664.93 million shares from the previous period [1] - Shanghai Pharmaceutical Industrial Research Institute Co., Ltd. remains the largest shareholder with 23,951.26 million shares, representing 17.86% of the total share capital, unchanged from the previous report [2] - China Pharmaceutical Investment Co., Ltd. and China National Pharmaceutical Group Corporation also maintained their holdings at 17,400.56 million shares (12.97%) and 15,309.16 million shares (11.41%), respectively [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares in the current period [3]